Abstract 472P
Background
Esophageal squamous cell carcinoma (ESCC) has a poor prognosis in Asian regions and the immunotherapy targeting PD-1 is on the stage of clinical trials. This study aims to investigate the prognostic effect of PD-1 expression in intratumoral and stromal tumor-infiltrating lymphocytes (TILs) on relapse and overall survival of ESCC patients.
Methods
A retrospective cohort study was conducted with recruiting 142 ESCC patients who received surgical treatment. Intratumoral and stromal PD-1 expression was tested by immunohistochemistry (IHC).
Results
The median follow-up time was 22 months and 21.1% patients were lost of follow-up. Cell counts and expression rate of intratumoral PD1+ TILs did not show any association with disease-free survival (DFS) and overall survival (OS). Expression rate of stromal PD1+ TILs did not have a significant relationship with DFS. The patients with expression rate of stromal PD1+ TILs >20% had the median OS being 19 months and the patients with expression rate ≤20% did not achieved median OS (p = 0.034). The adjusted HR of higher expression rate was 1.49 (95%CI 0.82, 2.60, p = 0.189) for OS. ESCC patients with ≤18 stromal PD1+ TILs/HPF had the median DFS being 10 months however the patients with >18 cells/HPF had the median DFS being 48 months (p = 0.037). The adjusted HR of > 18 stromal PD1+ TILs/HPF on DFS was 0.59 (95%CI 0.35, 1.01, p = 0.055). With reference to the patients of lower expression rate/higher cell counts of stromal PD1+ TILs, patients with lower expression rate/lower cell counts, higher expression rate/higher cell counts, and higher expression rate/lower cell counts, had the adjusted HR for DFS increased to 3.73, 3.36 and 3.99 (p for trend being 0.030) and the adjusted HRs for OS increased to 2.95, 3.64 and 3.82 (p for trend being 0.015), respectively.
Conclusions
Integration of expression rate and cell counts of stromal PD1+ TILs had a significant prognostic effect in terms of relapse and overall survival. Further studies are warranted to provide reference for immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Beijing Hospitals Authority.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
174P - Progression of computer aided diagnosis on gastric cancer
Presenter: Yingyan Yu
Session: Poster display session
Resources:
Abstract
175P - Hypermethylation of the PCDHB15 promoter predicts the prognosis in gastric cancer
Presenter: Yu-ting Lee
Session: Poster display session
Resources:
Abstract
176P - DCLK1 promotes tumour invasion and metastasis through epithelial-mesenchymal transition and the MEK/ERK pathway in esophageal squamous cell carcinoma
Presenter: Jiannan Yao
Session: Poster display session
Resources:
Abstract
177P - Comparison of nab-paclitaxel plus ramcirumab and paclitaxel plus ramcirumab in patients with pretreated metastatic gastric cancer
Presenter: Yosuke Horita
Session: Poster display session
Resources:
Abstract
178P - Chief cell in stomach have stem cell activity and potential to develop gastric cancer
Presenter: Akihiro Yamamura
Session: Poster display session
Resources:
Abstract
179P - Postoperative Adjuvant transarterial chemoembolization versus surgery alone for resected hepatocellular carcinoma: A propensity-score matching study
Presenter: Mingyu Chen
Session: Poster display session
Resources:
Abstract
180P - LHPP inhibit the cell proliferation and EMT via the TGFβ/SMAD3 signaling pathway in iCCA
Presenter: Dan Wang
Session: Poster display session
Resources:
Abstract
181P - The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
Presenter: Andrew Dean
Session: Poster display session
Resources:
Abstract
182P - Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less
Presenter: Adarsh Das
Session: Poster display session
Resources:
Abstract
183P - Epidemiologic profile of gastric cancer in East Azerbaijan, Iran: 2 years population-based cancer registry results
Presenter: Pooneh Jabbaripour
Session: Poster display session
Resources:
Abstract